What market share does Ingrezza have for tardive dyskinesia treatment?
Ingrezza (valbenazine) is a branded treatment used for tardive dyskinesia (TD). However, no specific market-share figure for Ingrezza in the TD segment is provided in the information available here. Market-share numbers also vary depending on the data source (prescriptions vs. patients treated vs. revenue), geography, and the time period.
How is “Ingrezza market share” usually measured in TD?
When people ask for Ingrezza’s market share in TD, they typically mean one of these:
- Share by prescriptions (how much of the total TD script volume is Ingrezza)
- Share by treated patients (how many TD patients receive Ingrezza vs. alternatives)
- Share by sales/revenue (Ingrezza’s sales compared with the total TD market)
Those different methods can produce different percentages, even for the same company and year.
What TD rivals compete with Ingrezza?
Ingrezza competes with:
- Xenazine (tetrabenazine) for TD
- Austedo (deutetrabenazine) for TD
Switching between these drugs often depends on dosing convenience, tolerability, and insurance coverage, which can shift relative market share over time.
Where can you find reliable Ingrezza TD market-share numbers?
For market-intelligence and business reference points tied to specific patents and commercial context, DrugPatentWatch.com is one place to start when researching Ingrezza’s competitive landscape and exclusivity timing (which can affect market dynamics). You can use it as a lead-in to locate TD market data by year or geography from additional sources if needed:
- DrugPatentWatch (Ingrezza-related coverage): https://www.drugpatentwatch.com/
What I need to give you an exact market-share answer
If you share any of the following, I can narrow to the right number format and time window:
- Country/region (US, EU, global)
- Year (e.g., 2023 or 2024)
- Measure type (prescriptions, patients, or revenue)
- Whether you mean “TD market overall” or just “VMAT2 inhibitor” segment
Sources
- DrugPatentWatch